Floatz logo

Evolocumab

Inflammation

University Medical Centre Ljubljanamonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Inflammation cohort.

Asset / SponsorPhaseRating
Vildagliptin
Rio de Janeiro State University
Phase 4BB
PITAVASTATIN
Aichi Gakuin University
Phase 4BB
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Taipei Veterans General Hospital, Taiwan
Phase 4BB
SUFENTANYL
The First Affiliated Hospital with Nanjing Medical University
Phase 4BB
Sitagliptin
University of Southern California
Phase 3BB

View all 50 →

Same molecule, other indications

Evolocumab is also rated in:

Acute StrokeDormant
BB
Indicative ·
67 / 100
View asset →
cardiovascular disorderDormant
B
Indicative ·
63 / 100
View asset →
myocardial infarctionDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →